Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alta Bates Summit Medical Center, Berkeley, U.S.
Intrathecal baclofen therapy in patients with multiple sclerosis is reviewed
August 18th, 2006
Intrathecal baclofen therapy (ITB) in patients with multiple sclerosis is reviewed. "ITB is a recognized therapy for severe spasticity of both spinal and cerebral origin, with documented positive clinical outcomes for many patients with multiple sclerosis (MS). This article reviews some specific considerations concerning the use of ITB in the MS population, based on the author's 10 years of clinical experience," scientists in the United States report. "The unpredictable and progressive nature of the disease affects the identification of appropriate goals, the patient's decision-making process, and the evaluation of the response to the treatment over...
Source: Biotech Law Weekly (2006-08-18)
|
